Core Insights - Evofem Biosciences is set to launch PHEXX®, a hormone-free contraceptive vaginal gel, in the UAE by 2026 following favorable pricing certificates from the Emirates Drug Establishment [1][2][3] Group 1: Product Overview - PHEXX® is the first and only locally-acting contraceptive gel approved by the FDA, designed to be applied before intercourse and works by maintaining a vaginal pH that is inhospitable to sperm [4] - The product contains lactic acid, citric acid, and potassium bitartrate, and is applied using a pre-filled applicator [4] Group 2: Market Expansion - The issuance of pricing certificates is a significant step for Evofem to diversify its revenue streams and enter new markets, particularly in the GCC and MENA regions [2][3] - Pharma 1, Evofem's licensee, holds exclusive commercialization rights for PHEXX® and SOLOSEC® in six GCC states and plans to expand into 15 additional countries [3] Group 3: Regulatory and Commercial Strategy - Pharma 1 is responsible for all aspects of distribution, sales, marketing, and regulatory approvals for PHEXX® and SOLOSEC® in the licensed territory [3] - The company aims to submit PHEXX® for marketing approval in other licensed countries following its approval in the UAE [3]

Core Points - Evofem Biosciences' shareholders did not approve the merger with Aditxt, leading to the termination of the merger agreement [1] - The company is now focusing on regaining a national stock listing and securing growth capital to achieve sustainable positive EBITDA by 2027 [2] - Evofem has two FDA-approved products: PHEXXI, a hormone-free contraceptive gel, and SOLOSEC, an oral antibiotic for bacterial vaginosis and trichomoniasis [3][5] Company Strategy - The company aims to deliver value for investors and healthcare providers by executing its long-term growth strategy [2] - Collaboration with Aditxt is expected to enhance the commercialization of Mitomic diagnostic tests for women's health conditions [2] Financial Performance - Evofem has experienced four consecutive years of net sales growth as of 2024 [3]

Core Viewpoint - Evofem Biosciences, Inc. has announced that its licensee Pharma 1 has filed for regulatory approval in the UAE to commercialize SOLOSEC, an FDA-approved treatment for bacterial vaginosis and trichomoniasis, targeting a launch in the first half of 2026 [1][2]. Company Overview - Evofem Biosciences focuses on innovative products for women's sexual and reproductive health, generating revenue from two FDA-approved products, SOLOSEC and PHEXXI [9][10]. - Pharma 1, an Emirati healthcare company, holds exclusive commercialization rights for SOLOSEC and PHEXXI in the MENA region, including the UAE, Kuwait, Saudi Arabia, and Qatar [2][13]. Product Details - SOLOSEC is a single-dose oral treatment for bacterial vaginosis and trichomoniasis, providing a complete course of therapy in just one dose [4][11]. - The prevalence of bacterial vaginosis in the MENA region ranges from 25% to 41%, with an estimated 1.0 million to 1.7 million women affected in the UAE alone [4][5]. Market Opportunity - The Gulf Cooperation Council (GCC) region has millions affected by bacterial vaginosis and trichomoniasis, indicating a significant market opportunity for SOLOSEC [2][6]. - The WHO estimated 156.3 million new cases of trichomoniasis globally in 2020, highlighting the ongoing need for effective treatments [5][8]. Strategic Goals - Pharma 1 aims to develop a commercial strategy for SOLOSEC and expects strong reception in the medical community and among patients seeking convenient treatment options [2][3]. - Evofem views this filing as a critical step towards expanding its revenue streams beyond the U.S. market [2][3].

Core Insights - Evofem Biosciences, Inc. has successfully concluded its "Say Vagina" campaign, which aimed to normalize clinical anatomical language and combat censorship in medical terminology, resulting in significant engagement and awareness [1][3][9] - The campaign led to a 130% increase in traffic to PHEXXI.com, making PHEXXI the most followed contraceptive brand on social media among healthcare providers [1][9] - Evofem plans to maintain the momentum from the campaign by launching SayVaginaStore.com, with proceeds from merchandise sales going to sexual and reproductive health charities [3] Company Overview - Evofem is focused on commercializing innovative products to address unmet needs in women's sexual and reproductive health, generating revenue from two FDA-approved products: PHEXXI and SOLOSEC [4][6] - PHEXXI is the first and only hormone-free, on-demand prescription contraceptive vaginal gel, while SOLOSEC is an FDA-approved oral antibiotic for treating bacterial vaginosis and trichomoniasis [5][6] Campaign Impact - The "Say Vagina" campaign generated over 2.5 million views across social media platforms and significantly increased engagement with patients, providers, and educators [9] - CEO Saundra Pelletier emphasized the campaign's role in transforming shame into empowerment and fostering open dialogue about women's health [3] Future Plans - Evofem is preparing for a Special Meeting of Stockholders on September 26, 2025, to discuss a merger with Aditxt, Inc., which will result in Evofem becoming a wholly owned subsidiary of Aditxt [8][10][14]

Core Points - Evofem Biosciences, Inc. CEO Saundra Pelletier is receiving the Trailblazing Female Founders Award at the 2025 STIMULATE Conference, highlighting her leadership in the sexual wellness industry [1][2] - The STIMULATE Conference is the only North American event dedicated to sexual wellness, innovation, and empowerment, recognizing female founders who are transforming reproductive health discussions [2] - The award coincides with Say Vagina Month, a campaign by Evofem aimed at destigmatizing vaginal health and promoting accurate language in healthcare [3] Company Overview - Evofem is focused on addressing unmet needs in women's sexual and reproductive health through innovative products, generating revenue from two FDA-approved products [6] - The company relaunched SOLOSEC in November 2024 and is promoting it alongside PHEXXI to OB/GYNs in the U.S., with plans to enter global markets through strategic partnerships [7] - Evofem has entered into a definitive agreement to be acquired by Aditxt, Inc., aiming to enhance women's health initiatives within Aditxt's social innovation platform, with a targeted close in the second half of 2025 [8] Product Information - PHEXXI® is the first and only hormone-free, on-demand prescription contraceptive vaginal gel, which has shown that nearly 90% of women using it improved or maintained their sexual satisfaction [4] - SOLOSEC® is an FDA-approved oral antibiotic for treating bacterial vaginosis and trichomoniasis, providing a complete course of therapy in just one dose [10]

Core Insights - Windtree Therapeutics has entered a contract with a Chinese pharmaceutical manufacturer to produce Evofem's PHEXXI, aiming to reduce manufacturing costs by over 50% by the end of 2026 [1][2][3] - The tech transfer process is currently underway, with validation batch manufacturing expected to begin in 2026, which is anticipated to generate revenue for Windtree [2][3] - Evofem has experienced four consecutive years of net sales growth for PHEXXI and is preparing to enter the UAE market in early 2026 [3] Company Developments - The manufacturing contract is part of a broader License and Supply Agreement established in March 2025 between Windtree and Evofem [4] - Windtree aims to become a revenue-generating company across various growing industries, focusing on overall profitability [5]

Core Insights - Evofem Biosciences reported a 6% increase in net sales for 2024, reaching $19.4 million, primarily driven by the sales of PHEXXI, a hormone-free contraceptive gel [1][4] - The company successfully reduced total operating expenses by 27% to $27.0 million, reflecting improved fiscal discipline [5][6] - The acquisition and relaunch of SOLOSEC contributed to revenue diversification and growth [2][4] Financial Performance - For the year ended December 31, 2024, net sales were $19.4 million compared to $18.2 million in 2023, with lower returns enhancing the gross to net ratio [4] - Total operating expenses decreased from $36.1 million in 2023 to $27.0 million in 2024, excluding a non-cash amortization expense of $0.6 million related to SOLOSEC [5][10] - The loss from operations improved significantly to $7.7 million in 2024 from $17.8 million in the previous year [6][7] Sales and Marketing Efficiency - Sales and marketing expenses as a percentage of net sales were 47% for 2024, the most favorable ratio since the launch of PHEXXI in 2020 [6][11] - In the fourth quarter of 2024, sales and marketing expenses were 31% of net sales, indicating improved efficiency [11] Quarterly Highlights - In Q4 2024, net sales reached $7.1 million, up from $4.8 million in Q4 2023, driven by increased PHEXXI sales and the addition of SOLOSEC [8][9] - Total operating expenses for Q4 2024 were $8.1 million, a slight decrease from $8.2 million in the prior year [9][10] - The loss from operations for Q4 2024 improved to $1.0 million compared to a loss of $3.4 million in Q4 2023 [11] Strategic Initiatives - The company is pursuing a merger with Aditxt, which includes a funding commitment of $1.5 million to be completed by April 7, 2025 [3] - A sourcing partnership with Windtree Therapeutics aims to reduce PHEXXI manufacturing costs and enhance U.S. operating margins [3] Product Portfolio - Evofem's product lineup includes PHEXXI, a hormone-free contraceptive gel, and SOLOSEC, an oral treatment for bacterial vaginosis and trichomoniasis, which was relaunched in November 2024 [2][16]

As filed with the Securities and Exchange Commission June 5, 2024 Registration Statement No. 333-276588 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 4 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADITXT, INC. (Exact name of registrant as specified in its charter) (Primary Standard Industrial Delaware 23219 82-3204328 (I.R.S. Employer Identification Number) Classification Code Number) 2569 Wyandotte St., Suite 101 Mountainview, CA 94043 (650) 87 ...

As filed with the Securities and Exchange Commission May 13, 2024 Registration Statement No. 333-276588 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADITXT, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 23219 82-3204328 (Address and telephone number of regis ...

As filed with the Securities and Exchange Commission February 14, 2024 Registration Statement No. 333-276588 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADITXT, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 23219 82-3204328 (I.R.S. Employer Identification N ...